Xianda shares: pesticide creation is the main theme of development

Since its establishment, this company has been pursuing the "dream of pesticide creation".

Take the road of new pesticide creation

As we all know, the prospects for the creation of new pesticides are bright, but the road is tortuous and the future is very slim

According to the research team's understanding, since its establishment, Xianda has been focusing on the research and development and production of selective and innovative herbicide technical materials and preparations

"At present, the company has 73 invention patents.

The research team also learned that the company's current production and sales of clethodim, clomazone, imazethapyr, and dimethomorph (fungicide) are among the top domestic products

In terms of overseas market development, several major products of the company have been registered in the United States, Europe, Australia, India, Brazil, Argentina, Paraguay and other countries and regions

"The company adheres to the close integration of technology with the market, focuses on technological innovation in the field of herbicides, and adheres to the unique'drum-shaped' business model of Xianda's unique R&D, production and marketing.

Looking forward to the future, the vision of Xianda shares is to advance technology and internationalization.

　　Capacity release drives market expansion

　　According to the plan, the first-phase 5,000-ton/year clethodim technical production line will be trial-produced within this year.

　　From the perspective of Xianda’s industrial chain structure, the sales of its technical materials account for most of the company’s revenue; from the perspective of product structure, the selective herbicide represented by clethodim is emphasized, and its sales scale approximately accounts for the company’s More than 80% of overall revenue

　　It can be seen that the price fluctuation of clethodim, the main product, plays a decisive role in the company's profits

　　Yao Changming told the research team: "At present, the domestic price of clethodim has dropped significantly compared with the same period, coupled with the increase in the price of main raw materials and the increase in costs, the company's profit in the third quarter of this year has been affected to a certain extent

　　The third quarter report showed that the company achieved revenue of 1.

　　But in the long run, Xianda shares will still have a leading edge in the global market in the future

　　According to the research team, first of all, Xianda has many years of experience in the production and sales of clethodim technical medicine, and has built up the advantages of production technology, brand competitiveness and channel barriers

　　At present, Xianda has realized that the original drug business and the preparation business complement each other